

CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application. The claims are amended and cancelled as described herein without prejudice. Applicant reserves the right to pursue amended or canceled subject matter in one or more timely filed divisional, continuation or continuation-in-part applications.

Claims 1-38. (Canceled)

Claim 39. (Currently Amended) A method of inhibiting the binding of TWEAK to a TWEAK receptor in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a composition comprising a TWEAK receptor antagonist wherein the TWEAK receptor comprises a sequence as set forth from amino acids 28-79 of SEQ ID NO:7, and the antagonist is selected from the group consisting of a soluble TWEAK receptor polypeptide that comprises the cysteine-rich repeat and binds TWEAK, an antibody that binds the TWEAK receptor, and an antisense nucleic acid [, a triple helix forming nucleic acid, a peptide, and a small molecule].

Claims 40-45. (Canceled)

Claim 46. (Currently Amended) A method of inhibiting angiogenesis in a mammal in need of such treatment comprising administering a therapeutically-effective amount of a composition comprising an antagonist of a TWEAK receptor, wherein the TWEAK receptor comprises a sequence as set forth from amino acids 28-79 of SEQ ID NO:7, and the antagonist is selected from the group consisting of a soluble TWEAK receptor that comprises the cysteine-rich repeat and binds TWEAK, an antibody that binds the TWEAK receptor, and an antisense nucleic acid.

Claim 47. (Previously Presented) The method of claim 46 wherein the composition further comprises a pharmaceutically acceptable carrier.

Claim 48. (Previously Presented) The method of claim 46 wherein the mammal is a human.

Claim 49. (Previously Presented) The method of claim 46 wherein the mammal has a disease or condition mediated by angiogenesis.

Claim 50. (Previously Presented) The method of claim 49 wherein the disease or condition is characterized by ocular neovascularization.

Claim 51. (Previously Presented) The method of claim 49 wherein the disease or condition is a malignant or metastatic condition.

Claim 52. (Previously Presented) The method of claim 51 wherein the malignant or metastatic condition is a solid tumor.

Claim 53. (Previously Presented) The method of claim 51 wherein the method further comprises treating the mammal with radiation.

Claim 54. (Previously Presented) The method of claim 51 wherein the method further comprises treating the mammal with a chemotherapeutic agent.

Claim 55. (Previously Presented) The method of claim 54 wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloid, plant-derived chemotherapeutics, nitrosoureas, antitumor antibiotics, antitumor enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists, hormone antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics, and biological response modifiers.

Claim 56. (Previously Presented) The method of claim 54 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, mechlorethamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, vinblastine, lymphokines, cytokines, interleukins, interferons, alpha interferon, beta interferon, delta interferon, TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone.

Claim 57. (Previously Presented) The method of claim 54 wherein the chemotherapeutic agent is selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists, TNF receptor antagonists, TRAIL, CD148 agonists, VEGF antagonists, VEGF receptor antagonists, and Tek antagonists.

Claim 58. (Cancelled)

Claim 59. (Currently Amended) The method of claim [58] 46 wherein the antagonist comprises an antibody that binds specifically to the TWEAK receptor extracellular domain.

Claim 60. (Previously Presented) The method of claim 59, wherein the antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, a transgenic antibody, and a human antibody.

Claim 61. (Previously Presented) The method of claim 59 wherein the antibody is conjugated to a radioisotope, a plant-derived toxin, a fungus-derived toxin, a bacterial-derived toxin, ricin A, diphtheria toxin, or a chemical poison.

Claim 62. (Previously Presented) The method of claim 59, wherein the mammal has a disease or condition mediated by angiogenesis.

Claim 63. (Previously Presented) The method of claim 62 wherein the disease or condition is characterized by ocular neovascularization.

Claim 64. (Previously Presented) The method of claim 62 wherein the disease or condition is a malignant or metastatic condition.

Claim 65. (Previously Presented) The method of claim 64 wherein the malignant or metastatic condition is a solid tumor.

Claim 66. (Previously Presented) The method of claim 64 wherein the method further comprises treating the mammal with radiation.

Claim 67. (Previously Presented) The method of claim 64 wherein the method further comprises treating the mammal with a chemotherapeutic agent.

Claim 68. (Previously Presented) The method of claim 67 wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloid, plant-derived chemotherapeutics, nitrosoureas, antitumor antibiotics, antitumor enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists, hormone antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics, and biological response modifiers.

Claim 69. (Previously Presented) The method of claim 67 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, mechlorethamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, vinblastine,

lymphokines, cytokines, interleukins, interferons, alpha interferon, beta interferon, delta interferon, TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone.

Claim 70. (Previously Presented) The method of claim 67 wherein the chemotherapeutic agent is selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists, TNF receptor antagonists, TRAIL, CD148 agonists, VEGF antagonists, VEGF receptor antagonists, and Tek antagonists.

Claim 71. (Currently Amended) The method of claim [58] 46 wherein the antagonist disrupts the interaction between the TWEAK receptor and a TRAF molecule.

Claims 72-90. (Canceled)